Dr Lal Pathlabs Ltd (LALPATHLAB) is currently trading at 1,961.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Dr Lal PathLabs is a nationwide diagnostic healthcare company offering pathology, radiology, cardiology, preventive screening and specialized diagnostic services to individual patients, hospitals, healthcare providers and corporates through an integrated laboratory and collection network. Q2 FY27 delivered the company’s strongest recent second-quarter revenue performance, with revenue rising 19.6% year-on-year to Rs. 874 crore. Growth was volume-led, supported by 13.6% sample growth and 9.0% patient growth, while EBITDA expanded faster than revenue because of operating leverage and cost efficiencies. The company is increasingly shifting from conventional diagnostics toward precision healthcare, with investments in genomics, oncology, transplant diagnostics, reproductive health, rare diseases and advanced biomarkers. Sovaaka, AI-enabled pathology applications and the Illumina NovaSeq platform support a more differentiated, higher-complexity service portfolio. Network expansion is extending beyond large cities: Tier 3-plus markets contributed 39% of FY26 revenue, compared with 34% in FY23. GraminFit has already served more than 100,000 patients in Q1 FY27 across approximately seven states, indicating a structured effort to unlock underserved rural preventive diagnostics. Dr Lal PathLabs combines scale with strong quality credentials, including 312 laboratories, more than 7,700 patient service centres, 53 NABL-accredited laboratories and two CAP-accredited laboratories. Its cash and cash equivalents reached Rs. 1,746 crore by H1 FY27, supporting expansion, innovation and shareholder distributions.

Over the past 52 weeks, Dr Lal Pathlabs Ltd has traded between a low of ₹1,272.00 and a high of ₹2,050.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Dr Lal Pathlabs Ltd has a market capitalization of approximately 34,055.69. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Dr Lal Pathlabs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 56.22 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 34,055.69 Cr, Dr Lal Pathlabs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Dr Lal Pathlabs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Dr Lal Pathlabs Ltd is 56.22. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Dr. Lal PathLabs reported consolidated profit of Rs 193.90 crore for the quarter ended 30 September 2026. The figure was Rs 170.50 crore in the preceding June 2026 quarter and Rs 152.20 crore in the September 2025 quarter.

LPL has approved an investment of up to Rs 49.5 crore in LPL Dubai. The consideration is cash, and LPL Dubai will remain a wholly owned subsidiary of LPL after the transaction.

Dr. Lal PathLabs paid Rs 20 crore in cash to acquire 100% of Shahbazkers Diagnostic Centre Private Limited. The transaction closed on 1 May 2026, and Shahbazkers became a wholly owned subsidiary.

Dr Lal PathLabs reported a 16.7% CAGR in Tier 3+ revenue from FY23 through FY26. Revenue increased from Rs 685 crore to Rs 1,090 crore, an absolute rise of Rs 405 crore.